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Summary Camptothecins are DNA topoisomerase I-directed anti-tumour drugs with a novel mechanism of
action. Topotecan (TPT), a hydrophilic derivative of camptothecin, is currently undergoing phase II clinical
trials in small-cell lung cancer (SCLC). Human SCLC OC-NYH cells were made more than 6-fold resistant to
topotecan by stepwise drug exposure and resistance was stable for 70 passages without drug. NYH/TPT cells
had half the topoisomerase I level and activity of wild-type cells. However, no difference in camptothecin or
topotecan inhibition of topoisomerase I-mediated DNA relaxation was found, indicating that the enzyme itself
was unchanged in the resistant cell. In NYH/TPT cells, topoisomerase IIa and P levels were increased
approximately 2-fold. Accordingly, the topoisomerase II-directed drug etoposide (VP-16) induced an increased
number of DNA single-strand breaks in NYH/TPT cells. However, sensitivity to different topoisomerase
Il-targeting agents in NYH/TPT cells varied from increased to decreased, indicating a role for as yet
unidentified factors acting on the pathway to cell death after topoisomerase TI-induced DNA damage has
occurred. Of 20 anti-cancer agents tested, only hydroxyurea showed marked collateral hypersensitivity in
NYH/TPT cells.
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Topoisomerase I is a nuclear enzyme which catalyses the
relaxation of supercoiled DNA by introducing transient
DNA single-strand breaks (SSBs). Camptothecin (CPT), a
topoisomerase I-targeting drug, is active against several ex-
perimental tumours. The drug interferes with the
breakage-reunion reaction by stabilising an enzyme-DNA
intermediate, termed the cleavable complex (Liu, 1989). Con-
siderable interest has been directed towards topoisomerase
I-active compounds as they represent a novel target for
anti-tumour drugs. As camptothecin is too toxic for clinical
use, several semisynthetic hydrophilic derivatives of camp-
tothecin have been developed. Among these, the charged
derivative topotecan (TPT, 9-dimethyl-amino-methyl-10-
hydroxycamptothecin) is currently undergoing phase II
clinical trials (Slichenmeyer et al., 1993). Several cell lines
have been selected for primary camptothecin and CPT-l1
[7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxycampto-
thecin] resistance, both in vivo and in vitro, by stepwise
continuous exposure or by mutagenic treatment. A major
feature ofresistance towards these agents is a reduced extrac-
table topoisomerase I activity reflecting a reduced content of
the enzyme. In addition, some camptothecin-resistant cell
lines display an altered topoisomerase I which is resistant to
inhibition of catalytic activity by camptothecin and is fre-
quently associated with a point mutation of the
topoisomerase I gene (Andoh et al., 1987; Gupta et al., 1988;
Tan et al., 1989; Eng et al., 1990; Kanzawa et al., 1990;
Sugimoto et al., 1990a; Chang et al., 1992; Kubota et al.,
1992; Woessner et al., 1992; Madelaine et al., 1993). Cell
lines with primary resistance to topotecan have not, to our
knowledge, previously been described in detail. Phase II trials
of topotecan in small-cell lung cancer (SCLC) are currently
in progress, and the purpose of our study was therefore to
describe possible mechanisms of resistance towards this pro-
mising new drug in a human SCLC cell line.
Materials and methods
Materials
A topoisomerase I activity kit was purchased from
TopoGEN, (Columbus, OH, USA). Scl-70 scleroderma
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antiserum expressing antibodies against topoisomerase I was
kindly provided by Dr Kurt Petersen, The Danish State
Serum Institute, Copenhagen, Denmark. Affinity-purified
polyclonal antibody directed against the C-terminus of
topoisomerase Ila was obtained from ICI Diagnostics (Cam-
bridge, UK). Affinity-purified polyclonal antibody against the
N-terminus oftopoisomerase IIP was a generous gift from Dr
Fritz Boege, University of Wiirtzburg, Germany. [Methyl-
3H]thymidine (25 Ci mmol-') and [2-'4CJthymidine
(50 Ci mmol') were purchased from Amersham (UK). All
other reagents were of analytical grade.
Drugs
Unlabelled topotecan (SmithKline Beecham Pharmaceuticals,
PA, USA) was dissolved in sterile water for in vitro studies
and further diluted in RPMI-1640 medium supplemented
with 10% fetal calf serum in studies on cells. ['4C]Topotecan
(35.6 mCimmolh') was a generous gift from Julia Christie
(SmithKline Beecham Pharmaceuticals). [3H]Daunorubicin
(0.88 Cimmol-') was purchased from DuPont NEN (Boston,
MA, USA). Alkeran (melphalan, Wellcome) was dissolved in
hydrochloric acid with ethanol and further diluted in pro-
pylene glycol phosphate buffer. m-AMSA (Parke-Davis) was
delivered in N,N-dimethylacetamide solution and further
diluted in acid lactose and Ara-C (cytosine arabinoside,
Upjohn) was dissolved in benzyl alcohol. All the solvents
used were dispensed by the manufacturers. Doxorubicin
(Farmitalia Carlo Erba), aclarubicin (Lundbeck), bleomycin
(Lundbeck), gemcitabine (Lilly), hydroxyurea (Bristol-Myers
Squibb), mitomycin C (Kyowa) and vincristine (Lilly) were
dissolved in sterile water. Vindesine (Lilly) was dissolved in
isotonic sodium chloride. Camptothecin (Sigma), taxotere
(Rhone-Poulenc Rohrer) and taxol (Bristol-Myers Squibb)
were dissolved in dimethylsulphoxide (DMSO). BCNU
(Bristol-Myers Squibb) was dissolved in 10% (v/v) ethanol in
sterile water. Mitoxantrone (Lederle), VP-16 (etoposide,
Bristol-Myers Squibb), VM-26 (teniposide, Bristol-Myers
Squibb) and cisplatin (Bristol-Myers Squibb) were in solution
for infusion. The drugs were diluted with tissue culture
medium to 300 x final concentrations, partitioned into multi-
ple aliquots, frozen on ethanol-dry ice and stored at - 80°C.
Just before culture application the contents of the frozen
vials were thawed and mixed. The cytotoxic stability of the
frozen drugs stored at - 80°C for 30-40 days was checkedTopotecan-resistant cell line
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by comparing with freshly diluted drug in a clonogenic assay.
All drugs were checked in this setting.
Cell lines
The human SCLC cell line OC-NYH (also designated GLC-
2) grows as a loosely attached monolayer in RPMI-1640
medium supplemented with 10% fetal calf serum plus penicil-
lin, streptomycin and L-glutamine at 37°C in a humidified
atmosphere with 7.5% carbon dioxide (Leij et al., 1985). The
topotecan-resistant subline NYH/TPT was established by
exposing OC-NYH cells to increasing concentrations of drug
over 1 year (54 passages) and was maintained at 38 nM
topotecan. The resistance was stable after 70 passages with-
out drug. In order to avoid genetic drift, the cell lines used in
experiments were re-established from frozen stocks at regular
intervals. Cell lines regularly tested negative for mycoplasma
contamination.
Clonogenic assay
Drug sensitivity was assessed by colony formation in soft
agar with a feeder layer containing sheep red blood cells as
previously described (Roed et al., 1987). Single-cell suspen-
sions (2 x 104 cells ml-') in RPMI-1640 supplemented with
10% fetal calf serum were plated with drugs in triplicate to
obtain 2000-3000 colonies in the control dishes (continuous
incubation). After 14-21 days the colonies were counted on
an image analysis system. The dose reducing the number of
colonies to 50% of controls (LD50) was determined by linear
regression analysis. When the calculated LD50 values were
above three times the highest tested concentration, the LD50
was assigned this value.
Preparation ofwhole-cell lysate
All steps were performed at 4°C. Exponentially growing cells
were harvested and washed twice in phosphate buffered
saline (PBS; 2.67 mM potassium chloride, 137 mM sodium
chloride, 1.45 mM sodium dihydrogen phosphate, 6.45 mM
disodium hydrogen phosphate, pH 7.4) supplemented with
1 mM benzamidine (Sigma), 1 mM Phenyl methyl sulphonyl
fluoride (PMSF, Sigma) and 10 yg ml-' soybean trypsin
inhibitor (Sigma). Cells were lysed with 0.2% SDS and
digested with 500 units ml-' Benzon nuclease (Alfred Ben-
zon, Denmark). An equal volume of 9M urea, 4% (v/v)
NP-40 and 2% (v/v) P-mercaptoethanol was added. Lysates
were used immediately after preparation.
Preparation ofcrude nuclear extracts
Crude nuclear extracts were performed by a modification of
a previously described method (Deffie et al., 1989). All steps
were performed at 4°C. Exponentially growing cells were
harvested and washed twice in nucleus buffer (NB) [2 mM
potassium dihydrogen phosphate, 5 mM magnesium chloride,
150 mm sodium chloride, 1 mM EGTA and 0.2 mM dithioth-
reitol (DTT), 1 mM PMSF, pH 6.5). Cells were resuspended
in 1 ml of NB and were lysed for 5 min by gently adding 9 ml
of NB supplemented with 0.3% (v/v) Triton X-100. Nuclear
pellets were spun down at 1000g for 10 min and washed with
NB. Proteins were extracted for 30 min in NB with 350mM
sodium chloride. Insoluble nuclear fragments were spun
down at 17 000g and the supernatant was collected. Extracts
were diluted in an equal volume of glycerol and stored at
-80°C. Protein concentrations were measured by the Brad-
ford protein assay (Bradford, 1976).
DNA topoisomerase I activity
Topoisomerase I activity was determined by the relaxation of
supercoiled DNA according to the manufacturer's recom-
mendations. The reaction mixtures consisted of 10 mM
Tris-HC1 pH 7.5, 1 mM EDTA, 100 mM sodium chloride,
0.25 jig of supercoiled DNA and crude nuclear extracts with
the indicated amount of protein in a total volume of 20yl.
Incubation was done at 37°C for 30 min and terminated by
adding 5fil of stop buffer containing 5% sarkosyl, 0.125%
bromophenol blue and 25% glycerol. Inhibition of
topoisomerase I activity was done by adding either topotecan
or camptothecin at the indicated concentrations to reaction
mixtures containing equal amounts of catalytic activity. Sam-
ples were applied onto 1% agarose gels. After elect-
rophoresis, gels were stained in ethidium bromide and photo-
graphed in UV light.
Immunodetection oftopoisomerase I and topoisomerase IIa
and
After heating the lysates or the nuclear extracts for 5 min at
50°C, the samples were immediately loaded on a 7%
SDS-PAGE gel containing 5% glycerol and electrophoresed
overnight. The proteins were transferred to Trans Blot, a
PVDF membrane (Bio-Rad) in a semidry electroblot system
(KemEnTec, Denmark). Membranes were blocked in 1%
bovine serum albumin (BSA) in TBS-T buffer (10 mM
Tris-HCl, pH 8.2, 150 mM sodium chloride, 0.05% Tween
20) for 1 h and probed with either scleroderma serum
(1:1500), topoisomerase IIa antibodies (1:1000) or
topoisomerase IIP antibodies (1:10000) for 1 h. Alkaline
phosphatase-conjugated rabbit anti-human or swine anti-
rabbit antibodies (Dako, Copenhagen, Denmark) were used
as secondary antibodies. All steps were performed at room
temperature. Quantitation of immunoreactive bands was
done by densitometric scanning.
Immunodetection ofP-glycoprotein
All steps were performed at 4°C. Exponentially growing cells
were harvested and washed twice in NB. Cells were lysed for
5 min in NB supplemented with 0.3% (v/v) Triton X-100.
After centrifugation for 5 min at 1700 g, the supernatant
containing the membrane fraction was collected. Western
blotting was performed as described above using the C219
(Centocor, Malvern, PA, USA) monoclonal antibody at
1 g ml-'.
Measurement ofDNA single-strand-breaks (SSBs)
DNA damage was quantitated by the alkaline elution filter
method, as described in detail by Kohn (1991). L1210 cells
used as internal standard were exposed to 100 ILM hydrogen
peroxide for 60 min on ice, corresponding to an irradiation
dose of 300 rad as described by Szmigiero and Studzian
(1988). Cells were treated with varying doses of topotecan or
VP-16 at 37°C for 60 min. Mixing of standard and experi-
mental cells was done immediately before lysis. DNA was
eluted at pH 12.1 under deproteinising conditions using a
Nucleopore filter (2.0 tiM pore size).
Fractions were collected at 20 min intervals for 2 h with an
elution rate of 0.125 ml min-'. DNA SSBs frequencies were
expressed in rad equivalents and calculated as described by
Kohn et al. (1981).
Drug accumulation
Cells were incubated at 37°C in 1 ml of PBS (57 mm sodium
chloride, 5 mM potassium chloride, 1.3 mM magnesium sul-
phate, 51 mM disodium hydrogen phosphate, 9 mM sodium
dihydrogen prosphate, pH 7.4) supplemented with 5% fetal
calf serum, 10 mM glucose and 5 gM ['4C]topotecan or S JIM
[3H]daunorubicin for periods of 120 and 180 min in poly-D-
lysine-coated wells. Drug accumulation was stopped by
rapidly washing wells four times in ice-cold PBS. After pro-
teolytic digestion, the suspension was aspirated and transfer-
red to counting vials and counted by liquid scintillation.
Cell volume
Cell volume was measured in a Coulter Counter (TM) using
standard beads for calibration.
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kkResults
General characteristics and sensitivity pattern
NYH/TPT cells are considerably larger and more rounded
with fewer neuronal-like pseudopodia than wild-type cells.
Table I summarises the cell characteristics. Twenty different
anti-tumour agents were tested on both cell lines in two
independent experiments, and the results are shown in Table
II.
DNA topoisomerase I activity
To ascertain whether resistance was related to an alteration
in topoisomerase I activity level, the catalytic activity in
nuclear extracts was measured. As shown in Figure 1, the
topoisomerase I activity in NYH/TPT extracts was reduced
to about half that of OC-NYH. We also examined whether
equal amounts of enzyme in extracts from the resistant cells
had altered sensitivity to the inhibitory effect ofcamptothecin
and topotecan compared with wild-type cells. At camp-
tothecin concentrations of 5, 10 and 50gLM (data not shown)
and topotecan concentrations of 25, 200 and 500lLM (Figure
2), inhibition of topoisomerase I activity in NYH/TPT cells
was similar to that of OC-NYH cells, indicating that no
qualitative alteration had occurred in the topoisomerase I
enzyme in this cell line.
Content ofimmunoreactive DNA topoisomerase I and IIoa and
The amount of topoisomerase I and IIa in nuclease-treated
whole-cell lysate and topoisomerase I and Ila and P in
nuclear extracts was measured by Western blotting in order
to determine whether quantitative reduction of the target
enzyme was responsible for the reduced topoisomerase I
Table I Cell characteristics of wild-type, OC-NYH and resistant,
NYH/TPT cells
Cell lines 2 Cell volumeb DNA indexc
OC-NYH 19 1240 1.28
NYH/TPT 24 1820 1.10
aDoubling time, T2, is indicated in hours. bCell volume is indicated
in fl. CDNA index is measured by flow cytometry.
Topotecan-resistant cell line
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activity. As shown in Figure 3a, the levels of immunoreactive
topoisomerase I in whole-cell lysates from NYH/TPT cells
were reduced compared with the wild-type level. In several
experiments the amount of topoisomerase I in NYH/TPT
cells varied between 0.6 and 0.75 of the wild-type level. In
contrast, the topoisomerase IIa level in NYH/TPT cells was
1.5-2.2 times the wild-type level in three independent
experiments (Figure 3b). In 350 mm sodium chloride nuclear
1 2 3 4 5 6 7 8 9 10
SC
Figure 1 DNA topoisomerase I activity in OC-NYH and NYH/
TPT cell lines. Enzymatic activity was determined by the relaxa-
tion of 0.25yg of supercoiled DNA at 37°C for 30 min with
350 mm sodium chloride nuclear extracts. SC and Rel represent
supercoiled and relaxed DNA respectively. Lanes 1 and 2 are
controls showing relaxed and supercoiled DNA without nuclear
extract respectively. Lanes 3-6, OC-NYH cells; lanes 7-10,
NYH/TPT cells; lanes 3 and 7, 0.75 glg of nuclear extract; lanes 4
and 8, 0.5 jig of nuclear extract; lanes 5 and 9, 0.3 iLg of nuclear
extract; lanes 6 and 10, 0.2 tLg of nuclear extract.
1 9 4 5 6 7 8 9 10
Figure 2 Inhibition of DNA topoisomerase I activity by
topotecan in OC-NYH and NYH/TPT cell lines. Enzymatic
activity was determined by the relaxation of 0.25 lg of super-
coiled DNA at 37°C for 30min with 350mm sodium chloride
nuclear extracts. Lane 1 is supercoiled DNA and lane 2 relaxed
DNA without nuclear extracts. Lanes 3-6, OC-NYH cells
(0.50 fig of nuclear extract); lanes 7-10, NYH/TPT cells (1.20 Ag
of nuclear extract); lanes 3 and 7, without topotecan; lanes 4 and
8, 25 tlM topotecan; lanes 5 and 9, 200itM topotecan; lanes 6 and
10, 500 jiM topotecan.
Table II The relative resistance to 20 anti-cancer agents in the topotecan-resistant
cell line NYH/TPT compared with the wild-type cell line OC-NYH
Drug
Aclarubicin
Alkeran
Ara-C
BCNU
Bleomycin
Camptothecin
Cisplatin
Doxorubicin
Gemcitabine
Hydroxyurea
m-AMSA
Mitoxantrone
Mitomycin
Taxol
Taxotere
Topotecan
Vincristine
Vindesine
Teniposide
Etoposide
LD50
11.5
581
45.6
16.4
56
2.4
478
32.8
3.10
145
56
12.7
20.4
1.6
0.31
4.0
1.3
1.6
13
150
OC-NYH
Range
11.2-11.7
555-608
45.3-46.0
16.1-16.7
27-85
2.3-2.6
474-482
27.4-38.3
3.06-3.13
136-153
51 -61
12.4- 13.1
18.5-21.6
1.65- 1.65
0.30-0.32
3.8-4.1
1.2-1.3
1.6-1.7
10-15
124- 176
LD50
17.3
1144
55.6
17.5
57
14
1860
31.3
4.08
80.9
91
18.0
35.3
1.69
0.38
26a
1.9
2.9
8.4
117
NYH/TPT
Range
14.2-19.3
1084-1205
54.0-57.2
14.0-21.0
34-81
12-17
1830- 1890
28.9-31.8
3.89-4.27
78.9-82.6
83-99
17.6-18.5
34.7-35.9
1.53-1.83
0.33-0.42
1.9-2.0
2.9-3.0
6.7- 10
110-124
Relative
resistance
1.5
1.8
1.2
1.1
1.0
5.9
3.9
0.95
1.3
0.56
1.6
1.4
1.6
1.0
1.3
6.6
1.5
1.8
0.67
0.78
The range and mean LDm values of two independent experiments are indicated in
nM, except for BCNU and hydroxyurea, which are shown in tM. Relative resistance
is calculated as the ratio of LD50 values in resistant and wild-type cells. aindicates
that the LD50 value is three times higher than the highest dose tested.Topotecan-resistant cell line
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extracts, topoisomerase I levels were 0.4-0.6 in NYH/TPT
cells, while topoisomerase IIa levels were 1.6 to 3.0-fold (data
not shown) and topoisomerase I1p levels were 2.0-fold in-
creased in NYH/TPT compared with OC-NYH cells (Figure
4). These results indicate that resistance in NYH/TPT cells is
a
1 2
b
1 2
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88
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56
correlated to a decreased topoisomerase I content. Further-
more, we observed that the increase in topoisomerase IIa is
an early event occurring before the decrease in topoisomerase
I level. Thus, cell lysates from an early passage (no. 38) with
unaltered topoisomerase I level had already reached a 2-fold
increase in topoisomerase IIa level, corresponding to the level
of the later-established NYH/TPT cells (Figure 5).
Drug-induced DNA damage in wild-type and NYH/TPT cells
In a dose-dependent manner, NYH/TPT cells were more
than 2 to 4-fold resistant to topotecan-induced DNA SSBs
190 (Figure 6). However, the reverse was true when cells were
treated with VP-16, a topoisomerase TI-targeting agent. m-
AMSA also induced an increased amount of DNA SSBs in
NYH/TPT cells (data not shown).
125
a 88
65
56
190 -
Figure 3 Western blot of DNA (a) topoisomerase I and (b) IIa
content in nuclease-treated whole-cell lysate in wild-type OC-
NYH (lane 1) and resistant NYH/TPT cells (lane 2). Topo I level
was reduced to 0.7 and topo Ila level was increased to 2.1 in
NYH/TPT as compared with wild-type cells. A 150pg aliquot of
protein was loaded onto each lane. Numbers indicate position
and size of the molecular weight markers in kDa.
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Figure 5 Western blot of DNA (a) topoisomerase I and (b) lla
content in nuclease-treated whole-cell lysate in OC-NYH (lane 1)
and NYH/TPT cells at passage 38 (lane 2) demonstrating a
2.0-fold increase in topoisomerase Ila but no change in
topoisomerase I. A 150jig aliquot of protein was loaded onto
each lane. Numbers to the left of each blot indicate position and
size of the molecular weight markers in kDa.
(n
.0 44
n3
c _
L >
._
U)- -az v 2(
*-as(
<~ 14
z
a
T TPTPT VP VP TrT TPTiTT Vy vr
5 10 20 1 3 5 10 20 1 3
OC-NYH NYH/TPT
Figure 4 Western blot of DNA topoisomerase Ilp content in
350mm nuclear extracts from wild-type OC-NYH (lane 1) and
resistant NYH/TPT cells (lane 2). Topo Ip was increased 2.0-
fold in NYH/TPT as compared with wild-type cells. A 70pg
aliquot of protein was loaded onto each lane. Samples were run
on the same gel and subsequently a non-relevant lane was cut
out. Numbers indicate position and size of the molecular weight
markers in kDa.
Figure 6 Drug-induced DNA damage in OC-NYH and NYH/
TPT cells after a I h drug exposure measured by the alkaline
elution filter method. Drugs were TPT = topotecan and
VP = etoposide (VP-16). Concentrations of drug are indicated in
JAM at the bottom. DNA single-strand breaks (SSBs) are exp-
ressed in rad equivalents (see Materials and methods). Bars
indicate range of two, or standard deviations of three, indepen-
dent experiments.
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Drug accumulation
Accumulation of ['4C]topotecan was not significantly reduced
in NYH/TPT cells. Furthermore, no P-glycoprotein was
detectable in a Western blot in NYH/TPT cells and
[3H]daunorubicin uptake was not increased in the presence of
25 JLM verapamil (data not shown). These results indicate that
no transport-mediated mechanisms contribute to resistance in
NYH/TPT cells and that selection by topotecan did not
induce overexpression of P-glycoprotein in these cells.
Discussion
As camptothecins represent a class of anti-cancer agents with
a novel mechanism of action, considerable efforts are cur-
rently directed towards the determination of the optimal
scheduling of these new compounds in cancer therapy. One
way of addressing this problem is to evaluate which
mechanism(s) of resistance the tumour cells will avail
themselves of. Topotecan and CPT-1 1 (irinotecan) are the
two topoisomerase I-directed drugs which are currently
undergoing phase II clinical trials. To our knowledge, the
present cell line is the first topotecan-resistant cell line that
has been characterised in detail, a resistance that was remark-
ably stable, being hardly reduced by 70 passages without
drug. However, several camptothecin-resistant cell lines have
been described. The most common feature associated with
camptothecin resistance is a reduced topoisomerase I activity
as a result of either a reduction in the content of the enzyme
or a mutation in the enzyme which renders itself less sensitive
to drug, or a combination of both (Andoh et al., 1987;
Gupta et al., 1988; Eng et al., 1990; Kanzawa et al., 1990;
Chang et al., 1991; Kubota et al., 1992; Tanizawa and Pom-
mier, 1992; Madelaine et al., 1993). NYH/TPT therefore
resembles camptothecin-resistant cells in reduction in target
activity.
Several observations indicate that camptothecin is not a
substrate for the P-glycoprotein efflux pump (Naito et al.,
1988; Chen et al., 1991). However, it has been shown that
cytotoxicity and accumulation of topotecan are reduced in
P-glycoprotein-overexpressing cells, and topotecan is believed
to be a weak substrate for P-glycoprotein (Hendricks et al.,
1992). It is therefore of interest that the NYH/TPT cells
showed no evidence of P-glycoprotein overexpression.
A major point in establishing a resistant cell line is to
determine its cross-resistance pattern, as this may have
clinical implications. Cellular resistance to topoisomerase I
drugs in cells with an unaltered or increased level of
topoisomerase II has been associated with an increased sen-
sitivity to topoisomerase II-targeting agents in several studies
(Gupta et al., 1988; Tan et al., 1989; Oguro et al., 1990;
Chang et al., 1991). This inverse sensitivity pattern of
topoisomerase I and II poisons could be caused by increased
dependence on topoisomerase II in cells with a deficient
topoisomerase I. The NYH/TPT line does indeed have a
marked increase in topoisomerase Ila and 1B content as well
as an increase in VP-16-induced SSBs. Further, we observed
that the increase in topoisomerase II levels is an early event,
occurring before the reduction in topoisomerase I, indicating
a need to compensate for damaged topoisomerase I functions
(Figure 5). However, it is curious that NYH/TPT cells were
cross-resistant to both mitoxantrone and m-AMSA,
especially as the number of m-AMSA-induced SSBs was
increased in NYH/TPT cells (data not shown). Also, given
the high expression of topoisomerase II and increased
number of SSBs caused by VP-16 in NYH/TPT, one would
have expected a more marked hypersensitivity to VP-16 in
this subline, as suggested by studies on CHO cells (Davies et
al., 1988). A similar cross-resistance to doxorubicin, VP-16
and m-AMSA in spite of a marked increase in topoisomerase
II levels was found in A549/CPT cells (Sugimoto et al.,
1990b). Further, CPT-11-resistant cells with lack of cross-
resistance or slight hypersensitivity to VP-16 and VM-26 also
demonstrate slight cross-resistance to doxorubicin (Kanzawa
et al., 1990). Thus, the relationship between topoisomerase II
levels and sensitivity to topoisomerase II-targeting agents in
topoisomerase I-resistant cell lines is complex, and
presumably other, as yet unidentified, factors act on the
pathway to cell death after topoisomerase 11-induced DNA
damage has occurred in NYH/TPT cells. Cross-resistance to
alkylating agents, as shown in Table II, varied from marked
(cisplatin, melphalan and mitomycin C) to none (BCNU).
No cross-resistance (Kanzawa et al., 1990) or slight hypersen-
sitivity (Oguro et al., 1990) to cisplatin has been reported in
cell lines resistant to camptothecin analogues. In this context,
it is interesting that a melphalan-resistant cell line has
decreased topoisomerase I and is cross-resistant to topotecan
(Friedman et al., 1994). On the other hand, hypersensitivity
to CPT-11 associated with increased topoisomerase I was
seen in cisplatin-resistant cells (Kotoh et al., 1994). These
data indicate that there is no straightforward relationship
between sensitivity to topoisomerase I-targeting agents and
alkylating agents. Hydroxyurea was the only drug tested with
marked collateral hypersensitivity (Table II). This could be
due to increased DNA repair as suggested by the cross-
resistance to cisplatin, a finding which merits further study as
to its mechanism.
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